is bpc 157 bad for your liver Multifunctionality and Possible Medical Application of the Peptide—Literature and Patent Review BPC-157: Experimental Peptide Creates Risk

For general background on how investigational peptides are evaluated for safety, the National Institutes of Healths overview of how experimental compounds move through clinical evaluation illustrates why oversight matters at every stage

BPC 157 markedly decreased the eNOS/Cav-1 binding and decreased Cav-1 binding, released the eNOS, and subsequently enhanced the activation of eNOS [121]

While some patients and clinics report benefits like more energy or less nausea, no large clinical trials have been conducted to confirm these claims

Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, total or partial gastrectomy